Trial Outcomes & Findings for TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers (NCT NCT03884556)

Last Updated: 2025-07-02

Results Overview

A DLT was defined as any clinically significant AE that occurred during Treatment Cycle 1 that the Investigator or Sponsor considered as possibly or likely related to TTX-030 as a single agent, or the combination of TTX-030 and other agent(s), and met the following criteria: NCI CTCAE Version 5.0 Grade 5 event, Grade 4 hematological or Grade≥3 non-hematological toxicities, or Grade≥3 irAEs. Laboratory abnormalities that were asymptomatic and deemed not clinically significant were not regarded as DLTs. During Dose Escalation, each dosing cohort was completed through the DLT observation window before escalation was allowed within its arm. In each Safety Lead-in cohort, all participants were closely monitored for the occurrence of DLTs.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

56 participants

Primary outcome timeframe

1 cycle (each cycle is 21-28 days)

Results posted on

2025-07-02

Participant Flow

Participant milestones

Participant milestones
Measure	Arm 1: TTX-030 0.5 mg/kg Participants in Arm 1 Escalation were administered IV 0.5 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 1.5 mg/kg Participants in Arm 1 Escalation were administered IV 1.5 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 3.0 mg/kg Participants in Arm 1 Escalation were administered IV 3.0 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 6.0 mg/kg Participants in Arm 1 Escalation were administered IV 6.0 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 10 mg/kg Participants in Arm 1 Escalation were administered IV 10 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 20 mg/kg Participants in Arm 1 Escalation were administered IV 20 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 40 mg/kg Participants in Arm 1 Escalation were administered IV 40 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1 Expansion: TTX-030 40 mg/kg Load, 30 mg/kg Q3W Participants in Arm 1 Expansion received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W.	Arm 2 (Safety Lead-in and Expansion), Combination Participants in Safety Lead-in portion and Expansion of Arm 2 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W and pembrolizumab IV at a dose of 200 mg on Day 1 of each 21-day treatment cycle.	Arm 4 (Safety Lead-In and Expansion) Participants in Safety Lead-in and Arm 4 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W and received gemcitabine 1000 mg/m\^2 + nab-Paclitaxel 125 mg/m\^2 Days 1, 8, and 15 every 28 days.
Overall Study STARTED	1	2	2	4	3	3	6	8	13	14
Overall Study COMPLETED	1	2	2	4	3	3	6	8	13	14
Overall Study NOT COMPLETED	0	0	0	0	0	0	0	0	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Arm 1: TTX-030 0.5 mg/kg n=1 Participants Participants in Arm 1 Escalation were administered IV 0.5 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 1.5 mg/kg n=2 Participants Participants in Arm 1 Escalation were administered IV 1.5 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 3.0 mg/kg n=2 Participants Participants in Arm 1 Escalation were administered IV 3 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 6.0 mg/kg n=4 Participants Participants in Arm 1 Escalation were administered IV 6 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 10 mg/kg n=3 Participants Participants in Arm 1 Escalation were administered IV 10mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 20 mg/kg n=3 Participants Participants in Arm 1 Escalation were administered IV 20 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 40 mg/kg n=6 Participants Participants in Arm 1 Escalation were administered IV 40 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1 Expansion: TTX-030 40 mg/kg Load/30 mg/kg Q3W n=8 Participants Participants in Expansion received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W.	Arm 2 (Safety Lead-in and Expansion), Combination n=13 Participants Participants in Safety Lead-in portion and Expansion of Arm 2 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W and pembrolizumab IV at a dose of 200 mg on Day 1 of each 21-day treatment cycle.	Arm 4 (Safety Lead-In and Expansion) n=14 Participants Participants in Safety Lead-in and Arm 4 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W and received gemcitabine 1000 mg/m\^2 + nab-Paclitaxel 125 mg/m\^2 Days 1, 8, and 15 every 28 days.	Total n=56 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants
Age, Categorical Between 18 and 65 years	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	2 Participants n=4 Participants	2 Participants n=21 Participants	2 Participants n=10 Participants	4 Participants n=115 Participants	4 Participants n=6 Participants	9 Participants n=6 Participants	6 Participants n=64 Participants	31 Participants n=17 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	2 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=10 Participants	2 Participants n=115 Participants	4 Participants n=6 Participants	4 Participants n=6 Participants	8 Participants n=64 Participants	25 Participants n=17 Participants
Age, Continuous	26 years n=5 Participants	73 years n=7 Participants	59.5 years n=5 Participants	63 years n=4 Participants	64 years n=21 Participants	59 years n=10 Participants	61.5 years n=115 Participants	64.5 years n=6 Participants	57 years n=6 Participants	66.5 years n=64 Participants	63.5 years n=17 Participants
Sex: Female, Male Female	1 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants	3 Participants n=4 Participants	3 Participants n=21 Participants	1 Participants n=10 Participants	2 Participants n=115 Participants	5 Participants n=6 Participants	6 Participants n=6 Participants	10 Participants n=64 Participants	34 Participants n=17 Participants
Sex: Female, Male Male	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	2 Participants n=10 Participants	4 Participants n=115 Participants	3 Participants n=6 Participants	7 Participants n=6 Participants	4 Participants n=64 Participants	22 Participants n=17 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	1 Participants n=6 Participants	0 Participants n=6 Participants	1 Participants n=64 Participants	2 Participants n=17 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	1 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	1 Participants n=17 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	3 Participants n=64 Participants	6 Participants n=17 Participants
Race (NIH/OMB) White	1 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants	3 Participants n=4 Participants	2 Participants n=21 Participants	2 Participants n=10 Participants	6 Participants n=115 Participants	6 Participants n=6 Participants	12 Participants n=6 Participants	10 Participants n=64 Participants	45 Participants n=17 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	1 Participants n=6 Participants	0 Participants n=64 Participants	2 Participants n=17 Participants
Region of Enrollment United States	1 participants n=5 Participants	2 participants n=7 Participants	2 participants n=5 Participants	4 participants n=4 Participants	3 participants n=21 Participants	3 participants n=10 Participants	6 participants n=115 Participants	8 participants n=6 Participants	13 participants n=6 Participants	14 participants n=64 Participants	56 participants n=17 Participants

PRIMARY outcome

Timeframe: 1 cycle (each cycle is 21-28 days)

Population: All participants in the Dose Escalation cohorts who received 1 infusion during the treatment cycle and completed safety evaluations through the end of the DLT period or experienced a DLT before the end of the DLT period (ie, participants started Cycle 2 or experienced a DLT).

Outcome measures

Outcome measures
Measure	Arm 1: TTX-030 1.5 mg/kg n=2 Participants Participants in Arm 1: TTX-030 was administered IV 1.5 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 3.0 mg/kg n=2 Participants Participants in Arm 1: TTX-030 was administered IV 3.0 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 6.0 mg/kg n=3 Participants Participants in Arm 1: TTX-030 was administered IV 6.0 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 10 mg/kg n=3 Participants Participants in Arm 1: TTX-030 was administered IV 10 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 20 mg/kg n=3 Participants Participants in Arm 1: TTX-030 was administered IV 20 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 40 mg/kg n=6 Participants Participants in Arm 1: TTX-030 was administered IV 40 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 40 mg/kg Participants in Arm 1: TTX-030 was administered IV 40 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 4 (Safety Lead-In and Expansion) Participants in Safety Lead-in and Arm 4 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W and received gemcitabine 1000 mg/m\^2 + nab-Paclitaxel 125 mg/m\^2 Days 1, 8, and 15 every 28 days.	Arm 2 (Safety Lead-in and Expansion), Combination Participants in Safety Lead-in portion and Expansion of Arm 2 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W and pembrolizumab IV at a dose of 200 mg on Day 1 of each 21-day treatment cycle.	Arm 4 (Safety Lead-In and Expansion) Participants in Safety Lead-in and Arm 4 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W and received gemcitabine 1000 mg/m\^2 + nab-Paclitaxel 125 mg/m\^2 Days 1, 8, and 15 every 28 days.
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—

PRIMARY outcome

Timeframe: Through study completion, an average of 1 year

Population: Participants in the Safety Analysis Set who had at least 1 post baseline evaluable tumor assessment unless death or clinical progressive disease (PD) occurred before the first post baseline disease assessment.

Anti-tumor activity in subjects treated with TTX-030 as single agent or in combination with specified regimens

Outcome measures

Outcome measures
Measure	Arm 1: TTX-030 1.5 mg/kg n=7 Participants Participants in Arm 1: TTX-030 was administered IV 1.5 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 3.0 mg/kg n=11 Participants Participants in Arm 1: TTX-030 was administered IV 3.0 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 6.0 mg/kg Participants in Arm 1: TTX-030 was administered IV 6.0 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 10 mg/kg Participants in Arm 1: TTX-030 was administered IV 10 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 20 mg/kg Participants in Arm 1: TTX-030 was administered IV 20 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 40 mg/kg Participants in Arm 1: TTX-030 was administered IV 40 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 40 mg/kg Participants in Arm 1: TTX-030 was administered IV 40 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 4 (Safety Lead-In and Expansion) Participants in Safety Lead-in and Arm 4 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W and received gemcitabine 1000 mg/m\^2 + nab-Paclitaxel 125 mg/m\^2 Days 1, 8, and 15 every 28 days.	Arm 2 (Safety Lead-in and Expansion), Combination Participants in Safety Lead-in portion and Expansion of Arm 2 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W and pembrolizumab IV at a dose of 200 mg on Day 1 of each 21-day treatment cycle.	Arm 4 (Safety Lead-In and Expansion) Participants in Safety Lead-in and Arm 4 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W and received gemcitabine 1000 mg/m\^2 + nab-Paclitaxel 125 mg/m\^2 Days 1, 8, and 15 every 28 days.
Objective Response Rate (ORR) - Arm 1 and Arm 2 Expansion Cohorts	7 percentage of participants Interval 0.0 to 41.0	9.1 percentage of participants Interval 0.2 to 41.3	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Through study completion, an average of 1 year

Anti-tumor activity in subjects treated with TTX-030 as single agent or in combination with specified regimens

Outcome measures

Outcome measures
Measure	Arm 1: TTX-030 1.5 mg/kg n=1 Participants Participants in Arm 1: TTX-030 was administered IV 1.5 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 3.0 mg/kg n=2 Participants Participants in Arm 1: TTX-030 was administered IV 3.0 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 6.0 mg/kg n=1 Participants Participants in Arm 1: TTX-030 was administered IV 6.0 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 10 mg/kg n=3 Participants Participants in Arm 1: TTX-030 was administered IV 10 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 20 mg/kg n=2 Participants Participants in Arm 1: TTX-030 was administered IV 20 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 40 mg/kg n=3 Participants Participants in Arm 1: TTX-030 was administered IV 40 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 40 mg/kg n=6 Participants Participants in Arm 1: TTX-030 was administered IV 40 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 4 (Safety Lead-In and Expansion) n=13 Participants Participants in Safety Lead-in and Arm 4 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W and received gemcitabine 1000 mg/m\^2 + nab-Paclitaxel 125 mg/m\^2 Days 1, 8, and 15 every 28 days.	Arm 2 (Safety Lead-in and Expansion), Combination Participants in Safety Lead-in portion and Expansion of Arm 2 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W and pembrolizumab IV at a dose of 200 mg on Day 1 of each 21-day treatment cycle.	Arm 4 (Safety Lead-In and Expansion) Participants in Safety Lead-in and Arm 4 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W and received gemcitabine 1000 mg/m\^2 + nab-Paclitaxel 125 mg/m\^2 Days 1, 8, and 15 every 28 days.
Objective Response Rate (ORR) (Except for Arm 1 and 2 Expansion Cohorts, Where ORR Was a Primary Endpoint)	1 percentage of participants Interval 0.0 to 97.5	2 percentage of participants Interval 0.0 to 84.2	1 percentage of participants Interval 0.0 to 97.5	3 percentage of participants Interval 0.0 to 70.8	2 percentage of participants Interval 0.0 to 70.8	3 percentage of participants Interval 0.0 to 70.8	6 percentage of participants Interval 0.0 to 45.9	30.8 percentage of participants Interval 9.1 to 61.4	—	—

SECONDARY outcome

Timeframe: Cycles 1-3 (each cycle is 21-28 days)

Population: Dose-Normalized PK Parameters of Serum TTX-030

PK parameters of serum TTX-030 by Arm and Dose - Cycle 1

Outcome measures

Outcome measures
Measure	Arm 1: TTX-030 1.5 mg/kg n=1 Participants Participants in Arm 1: TTX-030 was administered IV 1.5 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 3.0 mg/kg n=2 Participants Participants in Arm 1: TTX-030 was administered IV 3.0 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 6.0 mg/kg n=2 Participants Participants in Arm 1: TTX-030 was administered IV 6.0 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 10 mg/kg n=4 Participants Participants in Arm 1: TTX-030 was administered IV 10 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 20 mg/kg n=3 Participants Participants in Arm 1: TTX-030 was administered IV 20 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 40 mg/kg n=3 Participants Participants in Arm 1: TTX-030 was administered IV 40 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 40 mg/kg n=6 Participants Participants in Arm 1: TTX-030 was administered IV 40 mg/kg of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 4 (Safety Lead-In and Expansion) n=8 Participants Participants in Safety Lead-in and Arm 4 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W and received gemcitabine 1000 mg/m\^2 + nab-Paclitaxel 125 mg/m\^2 Days 1, 8, and 15 every 28 days.	Arm 2 (Safety Lead-in and Expansion), Combination n=13 Participants Participants in Safety Lead-in portion and Expansion of Arm 2 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W and pembrolizumab IV at a dose of 200 mg on Day 1 of each 21-day treatment cycle.	Arm 4 (Safety Lead-In and Expansion) n=13 Participants Participants in Safety Lead-in and Arm 4 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W and received gemcitabine 1000 mg/m\^2 + nab-Paclitaxel 125 mg/m\^2 Days 1, 8, and 15 every 28 days.
Maximum Plasma Concentration (Cmax)	4.91 Cmax (μg/mL) Geometric Coefficient of Variation 0	25.9 Cmax (μg/mL) Geometric Coefficient of Variation 8.2	35.2 Cmax (μg/mL) Geometric Coefficient of Variation 6.4	79.3 Cmax (μg/mL) Geometric Coefficient of Variation 49.3	188 Cmax (μg/mL) Geometric Coefficient of Variation 13.8	190 Cmax (μg/mL) Geometric Coefficient of Variation 75.8	629 Cmax (μg/mL) Geometric Coefficient of Variation 47.6	694 Cmax (μg/mL) Geometric Coefficient of Variation 56.8	647 Cmax (μg/mL) Geometric Coefficient of Variation 50.5	487 Cmax (μg/mL) Geometric Coefficient of Variation 27.3

Adverse Events

Arm 1: TTX-030 0.5 mg/kg

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Arm 1: TTX-030 1.5 mg/kg

Serious events: 1 serious events

Other events: 1 other events

Deaths: 1 deaths

Arm 1: TTX-030 3.0 mg/kg

Serious events: 1 serious events

Other events: 2 other events

Deaths: 1 deaths

Arm 1: TTX-030 6.0 mg/kg

Serious events: 1 serious events

Other events: 4 other events

Deaths: 1 deaths

Arm 1: TTX-030 10 mg/kg

Serious events: 1 serious events

Other events: 3 other events

Deaths: 1 deaths

Arm 1: TTX-030 20 mg/kg

Serious events: 0 serious events

Other events: 3 other events

Deaths: 2 deaths

Arm 1: TTX-030 40 mg/kg

Serious events: 4 serious events

Other events: 3 other events

Deaths: 3 deaths

Arm 1 Expansion: TTX-030 40 mg/kg Load/30 mg/kg Q3W

Serious events: 2 serious events

Other events: 6 other events

Deaths: 1 deaths

Arm 2 (Safety Lead-in and Expansion), Combination

Serious events: 6 serious events

Other events: 13 other events

Deaths: 4 deaths

Arm 4 (Safety Lead-In and Expansion)

Serious events: 4 serious events

Other events: 14 other events

Deaths: 7 deaths

Serious adverse events

Serious adverse events
Measure	Arm 1: TTX-030 0.5 mg/kg n=1 participants at risk Participants in Arm 1 Escalation were administered IV 0.5 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 1.5 mg/kg n=2 participants at risk Participants in Arm 1 Escalation were administered IV 1.5 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 3.0 mg/kg n=2 participants at risk Participants in Arm 1 Escalation were administered IV 3.0 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 6.0 mg/kg n=4 participants at risk Participants in Arm 1 Escalation were administered IV 6.0 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 10 mg/kg n=3 participants at risk Participants in Arm 1 Escalation were administered IV 10 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 20 mg/kg n=3 participants at risk Participants in Arm 1 Escalation were administered IV 20 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 40 mg/kg n=6 participants at risk Participants in Arm 1 Escalation were administered IV 40 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1 Expansion: TTX-030 40 mg/kg Load/30 mg/kg Q3W n=8 participants at risk Participants in Expansion received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W.	Arm 2 (Safety Lead-in and Expansion), Combination n=13 participants at risk Participants in Safety Lead-in portion and Expansion of Arm 2 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W and pembrolizumab IV at a dose of 200 mg on Day 1 of each 21-day treatment cycle.	Arm 4 (Safety Lead-In and Expansion) n=14 participants at risk Participants in Safety Lead-in and Arm 4 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W and received gemcitabine 1000 mg/m\^2 + nab-Paclitaxel 125 mg/m\^2 Days 1, 8, and 15 every 28 days.
Blood and lymphatic system disorders Anemia	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	50.0% 1/2 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	16.7% 1/6 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.7% 1/13 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Gastrointestinal disorders Ascites	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	16.7% 1/6 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Cardiac disorders Angina pectoris	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.7% 1/13 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Cardiac disorders Cardiac arrest	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.7% 1/13 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Gastrointestinal disorders Colitis	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.7% 1/13 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Gastrointestinal disorders Vomiting	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.1% 1/14 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Hepatobiliary disorders Autoimmune hepatitis	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.7% 1/13 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Gastrointestinal disorders Oesophageal haemorrhage	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	16.7% 1/6 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
General disorders Generalized edema	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	12.5% 1/8 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Hepatobiliary disorders Hyperbilirubinemia	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	50.0% 1/2 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Immune system disorders Allergy to arthropod sting	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	50.0% 1/2 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Infections and infestations Septic shock	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.7% 1/13 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.1% 1/14 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Infections and infestations Covid-19	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.1% 1/14 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Infections and infestations Extradural abscess	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.7% 1/13 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Infections and infestations Sepsis	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	25.0% 1/4 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.7% 1/13 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.7% 1/13 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	33.3% 1/3 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Nervous system disorders Syncope	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	16.7% 1/6 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Psychiatric disorders Mental status changes	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	12.5% 1/8 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.7% 1/13 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Psychiatric disorders Confusional state	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	16.7% 1/6 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Renal and urinary disorders Urinary tract obstruction	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	16.7% 1/6 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Respiratory, thoracic and mediastinal disorders Dyspnea	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	12.5% 1/8 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.7% 1/13 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.7% 1/13 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.1% 1/14 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Respiratory, thoracic and mediastinal disorders Obstructive airways disorder	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.7% 1/13 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Vascular disorders Embolism	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.1% 1/14 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.

Other adverse events

Other adverse events
Measure	Arm 1: TTX-030 0.5 mg/kg n=1 participants at risk Participants in Arm 1 Escalation were administered IV 0.5 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 1.5 mg/kg n=2 participants at risk Participants in Arm 1 Escalation were administered IV 1.5 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 3.0 mg/kg n=2 participants at risk Participants in Arm 1 Escalation were administered IV 3.0 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 6.0 mg/kg n=4 participants at risk Participants in Arm 1 Escalation were administered IV 6.0 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 10 mg/kg n=3 participants at risk Participants in Arm 1 Escalation were administered IV 10 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 20 mg/kg n=3 participants at risk Participants in Arm 1 Escalation were administered IV 20 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1: TTX-030 40 mg/kg n=6 participants at risk Participants in Arm 1 Escalation were administered IV 40 mg/kg dose of TTX-030 Q3W on the first day of each 21-day treatment cycle.	Arm 1 Expansion: TTX-030 40 mg/kg Load/30 mg/kg Q3W n=8 participants at risk Participants in Expansion received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W.	Arm 2 (Safety Lead-in and Expansion), Combination n=13 participants at risk Participants in Safety Lead-in portion and Expansion of Arm 2 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W and pembrolizumab IV at a dose of 200 mg on Day 1 of each 21-day treatment cycle.	Arm 4 (Safety Lead-In and Expansion) n=14 participants at risk Participants in Safety Lead-in and Arm 4 received TTX-030 IV loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W and received gemcitabine 1000 mg/m\^2 + nab-Paclitaxel 125 mg/m\^2 Days 1, 8, and 15 every 28 days.
General disorders Muscular weakness	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	33.3% 1/3 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	16.7% 1/6 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	25.0% 2/8 • Number of events 2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Gastrointestinal disorders Nausea	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	50.0% 1/2 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	25.0% 1/4 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	33.3% 1/3 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	12.5% 1/8 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	15.4% 2/13 • Number of events 2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	50.0% 7/14 • Number of events 7 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Blood and lymphatic system disorders Neutropenia	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	35.7% 5/14 • Number of events 5 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
General disorders Pyrexia	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	23.1% 3/13 • Number of events 3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Nervous system disorders Headache	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	33.3% 1/3 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	16.7% 1/6 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	12.5% 1/8 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	100.0% 1/1 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	25.0% 1/4 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	16.7% 1/6 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Investigations Weight decreased	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	25.0% 1/4 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	16.7% 1/6 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	12.5% 1/8 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	15.4% 2/13 • Number of events 2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	21.4% 3/14 • Number of events 3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	28.6% 4/14 • Number of events 4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Gastrointestinal disorders Vomiting	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	50.0% 1/2 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	33.3% 1/3 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	25.0% 2/8 • Number of events 2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	35.7% 5/14 • Number of events 5 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Nervous system disorders Dizziness	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	33.3% 1/3 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	33.3% 1/3 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	16.7% 1/6 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Metabolism and nutrition disorders Hypokalemia	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.7% 1/13 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	21.4% 3/14 • Number of events 3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Injury, poisoning and procedural complications Fall	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	21.4% 3/14 • Number of events 3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Metabolism and nutrition disorders Hypoalbuminemia	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	50.0% 1/2 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	25.0% 1/4 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	16.7% 1/6 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
General disorders Fatigue	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	50.0% 1/2 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	66.7% 2/3 • Number of events 2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	33.3% 2/6 • Number of events 2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	50.0% 4/8 • Number of events 4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	46.2% 6/13 • Number of events 6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	71.4% 10/14 • Number of events 10 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	50.0% 1/2 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	50.0% 1/2 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	25.0% 2/8 • Number of events 2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	23.1% 3/13 • Number of events 3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	21.4% 3/14 • Number of events 3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Gastrointestinal disorders Abdominal pain	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	15.4% 2/13 • Number of events 2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	21.4% 3/14 • Number of events 3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	42.9% 6/14 • Number of events 6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Blood and lymphatic system disorders Anemia	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	33.3% 2/6 • Number of events 2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	12.5% 1/8 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	38.5% 5/13 • Number of events 5 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	28.6% 4/14 • Number of events 4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Injury, poisoning and procedural complications Back pain	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	23.1% 3/13 • Number of events 3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	14.3% 2/14 • Number of events 2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Investigations Blood creatinine increased	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	23.1% 3/13 • Number of events 3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/14 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Gastrointestinal disorders Constipation	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	30.8% 4/13 • Number of events 4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	35.7% 5/14 • Number of events 5 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	25.0% 1/4 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	16.7% 1/6 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	12.5% 1/8 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	35.7% 5/14 • Number of events 5 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Metabolism and nutrition disorders Dehydration	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	66.7% 2/3 • Number of events 2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	16.7% 1/6 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	12.5% 1/8 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.7% 1/13 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	21.4% 3/14 • Number of events 3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Gastrointestinal disorders Diarrhea	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	33.3% 1/3 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	33.3% 1/3 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	25.0% 2/8 • Number of events 2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	15.4% 2/13 • Number of events 2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	42.9% 6/14 • Number of events 6 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Respiratory, thoracic and mediastinal disorders Dyspnea	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	33.3% 2/6 • Number of events 2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	25.0% 2/8 • Number of events 2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	30.8% 4/13 • Number of events 4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	7.1% 1/14 • Number of events 1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.
Nervous system disorders Edema peripheral	0.00% 0/1 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/2 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	50.0% 3/6 • Number of events 3 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/8 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	0.00% 0/13 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.	28.6% 4/14 • Number of events 4 • Up to 30 days from the last dose of TTX-030, a maximum duration of 2 years of treatment Safety population = all participants who received at least one dose or any partial dose of TTX-030.

Additional Information

Trishula Info

Trishula Therapeutics

Phone: (650) 509-5732

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place